By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

Results of a multicenter clinical trial found that adding the investigational adenoviral-based viral immunotherapy ...

The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...

Data from the PROTEUS trial showed that adding a hormone-blocking pill called apalutamide to standard hormone therapy, both ...

Peer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free survival (DFS) in patients with localized prostate cancer undergoing standard-of-care radiotherapy with ...

Aglatimagene is an investigational therapy that uses a modified virus to deliver a cancer-fighting gene into tumor cells.

Johnson & Johnson's prostate cancer drug Erleada, reportedly used alongside standard home-blocking therapy before and after ...

Johnson & Johnson’s PROTEUS Phase 3 trial shows apalutamide + hormone therapy before/after surgery improves outcomes in ...

Data from a late-stage trial, presented on Sunday, indicate that the treatment, administered six months before and after ...

The UCLA trial is currently enrolling patients. Clinical trial compares two targeted radiation therapies for recurrent prostate cancer. New AI tool, ProCUSNet, detects prostate cancer more accurately ...

New research suggests that men who take multivitamins after being diagnosed with prostate cancer may have a lower risk of cancer recurrence. In the overall study group, current multivitamin users ...

Beyond the physical, a prostate cancer diagnosis carries significant emotional weight. Understanding this spectrum of ...